⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719221 | 1.00 | — | — | |
| SCHEMBL2893192 | 1.00 | — | — | |
| SCHEMBL28347651 | 0.97 | — | — | |
| Allyl Alcohol SCHEMBL28659767 | 0.81 | TSHR (0.60) | — | |
| SCHEMBL899456 | 0.81 | — | — | |
| Ethoxycarbonyl Group SCHEMBL28100932 | 0.79 | TSHR (0.31) | — | |
| Propene SCHEMBL20398406 | 0.79 | TSHR (0.41) | — | |
| SCHEMBL3049981 | 0.78 | — | — | |
| SCHEMBL14819012 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL9915253 | 0.78 | TRPA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11325891-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210179570-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2015087351-A2 | PROCESS FOR THE PREPARATION OF (1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-[(1E)-1-METHYL-2-(2-METHYL-4-THIAZOLYL)ETHENYL]-17-OXA-4-AZABICYCLO[14.1.0]HEPTADECANE-5,9-DIONE AND INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-06-18 | — | — | WO | disclosed |
| EP-1813611-B1 | 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-2083844-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8377874-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |